BCL2 and follicular lymphoma: The paradigm for this is aberrant BCL-2 expression through chromosomal translocation in follicular lymphoma though increased anti-apoptotic BCL-2 protein expression occurs across diverse cancer types through mechanisms including gene amplification, increased transcription or translation and protein stability [3, 4].